Edwards Lifesciences Presents 5-Year Follow Up Data From PARTNER Trials Showing Clinical Outcomes For Female And Small Annulus Patients With Transcatheter Aortic Valve Replacement At The New York Valves 2024: The Structural Heart Summit
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences (NYSE:EW) presented five-year follow-up data from the PARTNER Trials at the New York Valves 2024: The Structural Heart Summit, showing excellent clinical outcomes and valve durability for patients with small annulus undergoing transcatheter aortic valve replacement (TAVR). The analysis revealed no association between clinical outcomes or valve durability and severe prothesis-patient mismatch (PPM) or higher mean gradients.
June 05, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences presented positive five-year follow-up data from the PARTNER Trials, showing excellent clinical outcomes and valve durability for TAVR patients with small annulus. This could boost investor confidence in the company's products and services.
The positive long-term data from the PARTNER Trials presented by Edwards Lifesciences is likely to enhance investor confidence in the company's TAVR products, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100